Mumbai, May 15 (IANS) The Central Drugs Standard Control Organisation (CSDCO) on Wednesday approved Boehringer Ingelheim’s Spevigo (Spesolimab) injection, a first-in-class treatment fo… Read More
Boehringer-Ingelheim’s intravenous Spevigo (spesolimab) is a therapy specifically indicated to treat active Generalized Pustular Psoriasis (GPP) flares. Nearly 90% of dermatologists… Read More
In 2022, the Food and Drug Administration (FDA) approved 37 new drugs for a wide range of medical conditions, including cancer, dermatological disorders, rare diseases, and autoimmune disord… Read More
Psoriasis is a common, chronic skin condition that results in rashes and itchy scaly patches. The rashes can be painful, distracting and even interfere with sleep. A rare variation of psoria… Read More
The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel, sele… Read More